PMID- 28973352
OWN - NLM
STAT- MEDLINE
DCOM- 20171031
LR  - 20180518
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
VI  - 102
IP  - 10
DP  - 2017 Oct 1
TI  - Plasma Leucine-Rich alpha-2-Glycoprotein 1 Predicts Rapid eGFR Decline and 
      Albuminuria Progression in Type 2 Diabetes Mellitus.
PG  - 3683-3691
LID - 10.1210/jc.2017-00930 [doi]
AB  - CONTEXT: Abnormal angiogenesis plays an important role in pathogenesis of 
      diabetic kidney disease (DKD). Leucine-rich alpha-2 glycoprotein 1 (LRG1) is a newly 
      identified angiogenic factor. OBJECTIVE: To study whether plasma LRG1 may 
      independently predict progression of DKD in individuals with type 2 diabetes 
      mellitus (T2DM). DESIGN AND SETTING: Prospective cohort study in a regional 
      hospital. PATIENTS: In total, 1226 T2DM participants were followed for a mean +/- 
      standard deviation (SD) of 3.1 +/- 0.4 years. MAIN OUTCOMES: Albuminuria 
      progression was defined as elevation in albuminuria level to a higher category. 
      Chronic kidney disease (CKD) progression [rapid estimated glomerular filtration 
      rate (eGFR) decline] was defined as a 40% or greater deterioration in eGFR in 3 
      years. RESULTS: Both participants with albuminuria progression and those with CKD 
      progression had higher plasma LRG1 levels at baseline. LRG1 independently 
      predicted albuminuria progression above traditional risk factors, including 
      baseline eGFR and urine albumin to creatinine ratio. A 1-SD increment in LRG1 was 
      associated with a 1.26-fold [95% confidence interval (CI), 1.04 to 1.53, P = 
      0.018] higher adjusted risk for albuminuria progression. The association of LRG1 
      with microalbuminuria to macroalbuminuria progression was stronger than its 
      association with normoalbuminuria to microalbuminuria progression [odds ratio 
      (OR), 1.51; 95% CI, 1.04 to 2.18, P = 0.029 vs OR, 1.09; 95% CI, 0.86 to 1.37, P 
      = 0.486, per 1-SD LRG1 increment]. Also, LRG1 independently predicted CKD 
      progression above traditional risk factors. A 1-SD increment in LRG1 was 
      associated with a 1.48-fold (95% CI, 1.04 to 2.11, P = 0.032) higher adjusted 
      risk for CKD progression. CONCLUSIONS: Plasma LRG1 predicts both albuminuria and 
      CKD progression beyond traditional risk factors. It may play a role in the 
      pathologic pathway leading to progression of DKD in T2DM.
CI  - Copyright (c) 2017 Endocrine Society
FAU - Liu, Jian-Jun
AU  - Liu JJ
AD  - Clinical Research Unit, Khoo Teck Puat Hospital, Singapore 768828, Singapore.
FAU - Pek, Sharon Li Ting
AU  - Pek SLT
AD  - Clinical Research Unit, Khoo Teck Puat Hospital, Singapore 768828, Singapore.
FAU - Ang, Kevin
AU  - Ang K
AD  - Clinical Research Unit, Khoo Teck Puat Hospital, Singapore 768828, Singapore.
FAU - Tavintharan, Subramaniam
AU  - Tavintharan S
AD  - Diabetes Centre, Khoo Teck Puat Hospital, Singapore 768828, Singapore.
FAU - Lim, Su Chi
AU  - Lim SC
AD  - Diabetes Centre, Khoo Teck Puat Hospital, Singapore 768828, Singapore.
CN  - SMART2D study
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
RN  - 0 (Biomarkers)
RN  - 0 (Glycoproteins)
RN  - 0 (LRG1 protein, human)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Albuminuria/blood/complications/*diagnosis/physiopathology
MH  - Biomarkers/blood
MH  - Cohort Studies
MH  - Diabetes Mellitus, Type 2/blood/complications/*diagnosis/physiopathology
MH  - Diabetic Nephropathies/blood/*diagnosis/physiopathology
MH  - Disease Progression
MH  - Female
MH  - Follow-Up Studies
MH  - *Glomerular Filtration Rate
MH  - Glycoproteins/analysis/*blood
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Renal Insufficiency, Chronic/blood/complications/*diagnosis/physiopathology
EDAT- 2017/10/04 06:00
MHDA- 2017/11/01 06:00
CRDT- 2017/10/04 06:00
PHST- 2017/04/19 00:00 [received]
PHST- 2017/06/27 00:00 [accepted]
PHST- 2017/10/04 06:00 [pubmed]
PHST- 2017/11/01 06:00 [medline]
PHST- 2017/10/04 06:00 [entrez]
AID - 3903089 [pii]
AID - 10.1210/jc.2017-00930 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 2017 Oct 1;102(10):3683-3691. doi: 
      10.1210/jc.2017-00930.